Documents
Resources
Learning Center
Upload
Plans & pricing Sign in
Sign Out

Nautilus Neurosciences, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile

VIEWS: 9 PAGES: 20

Nautilus Neurosciences, Inc. (Nautilus) is a pharmaceutical company, based in the US. The company operates on neurology. It identifies and develops drugs for neurological disorders. The product of the company CAMBIA is the prescription non-steroidal anti-inflammatory drug (NSAID) which may increase the chance of a heart attack or stroke that leads to death for the treatment of migraine in adults. It has backed by Tailwind Capital and Galen Partners a private equity firm that invests in health care, business services and media and communication companies. The company has launched its lead novel product CAMBIA in the US. Its product is FDA approved. Nautilus is headquartered in Bedminster, New Jersey, the US.

More Info
									               Nautilus Neurosciences, Inc. - Pharmaceuticals & Healthcare - Deals and
                                          Alliances Profile
       Reference Code: GDPH212929D                                                                                                              Publication Date: JAN 2013

      Company Overview                                                                                        Key Facts
      Nautilus Neurosciences, Inc. (Nautilus) is a pharmaceutical company, based in the
                                                                                                              Nautilus Neurosciences, Inc., Pharmaceuticals &
      US. The company operates on neurology. It identifies and develops drugs for
                                                                                                              Healthcare, Key Facts
      neurological disorders. The product of the company CAMBIA is the prescription non-
      steroidal anti-inflammatory drug (NSAID) which may increase the chance of a heart                        Web Address                            www.nautilusneuroscien
      attack or stroke that leads to death for the treatment of migraine in adults. It has                                                            ces.com
      backed by Tailwind Capital and Galen Partners a private equity firm that invests in
                                                                                                               Revenue (US$ million)                                 NA
      health care, business services and media and communication companies. The
      company has launched its lead novel product CAMBIA in the US. Its product is FDA                         Number of Employees                                   NA
      approved.                                                                                                GlobalData

      Financial Deals Landscape
        Nautilus Neurosciences, Inc., Pharmaceuticals & Healthcare,                       Nautilus Neurosciences, Inc., Pharmaceuticals &
        Deals by Type, 2007 to YTD 2013                                                   Healthcare, Deals By Year, 2007 to YTD 2013

                                                                                                          5
                                                                                                                                            4
                                                                                                          4

                                                                                           No. of Deals   3
                                                                                                                                   2
                                                                                                          2

                                                                                                          1
                                                                                                                 0         0                          0    0          0
                                                                                                          0
                                                                                                               2007       2008   2009      2010   2011    2012       YTD
                                                                                                                                                                     2013


                                                                                          Note: Deals include all announced pharmaceuticals & healthcare deals
         Note: Deals include all announced pharmaceuticals & healthcare deals from        from 2006 onwards, GlobalData
         2006 onwards, GlobalData


         Nautilus Neurosciences, Inc., Pharmaceuticals &                                  Nautilus Neurosciences, Inc., Pharmaceuticals &
         Healthcare, Deals By Region, 2007 to YTD 2013                                    Healthcare, Deals By Therapy Area, 2007 to YTD 2013

                         8                                                                                8
                               6                                                                                      6
          No. of Deals




                                                                                           No. of Deals




                         6                                                                                6

                         4                                                                                4

                         2                                                                                2
                                        0         0        0         0                                                                 0          0              0
                         0                                                                                0
                             North    Asia-     Europe   Middle   South                                          Central         Cardiova Metabolic       Pharmac
                             Americ   Pacific             East     and                                           Nervous          scular  Disorder         euticals
                               a                          and     Central                                        System                       s              and
                                                         Africa   Americ                                                                                  Healthcar
                                                                    a                                                                                         e



         Note: Deals include all announced pharmaceuticals & healthcare deals             Note: Deals include all announced pharmaceuticals & healthcare deals
         from 2006 onwards, GlobalData                                                    from 2006 onwards, GlobalData




Nautilus Neurosciences, Inc. - Pharmaceuticals & Healthcare -                                                                                     Reference Code: GDPH212929D
Deals and Alliances Profile
Source : www.globalcompanyintelligence.com                                                                                                                                     Page 1
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
       Table of Contents
       Table of Contents ............................................................................................................................................................................... 2
          List of Tables .................................................................................................................................................................................. 3
          List of Figures ................................................................................................................................................................................. 3
       Nautilus Neurosciences, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013 .................................................... 3
       Nautilus Neurosciences, Inc., Pharmaceuticals & Healthcare Deals By Type, 2007 to YTD 2013 ..................................................... 5
       Nautilus Neurosciences, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2007 to YTD 2013 ................................................ 6
       Nautilus Neurosciences, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2007 to YTD 2013 ...................................... 7
       Nautilus Neurosciences, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2007 to YTD 2013.................................................. 8
       Nautilus Neurosciences, Inc., Pharmaceuticals & Healthcare, Deal Details ....................................................................................... 9
          Asset Purchase............................................................................................................................................................................... 9
             Nautilus Neurosciences Acquires Diclofenac Products From Kowa Pharma .............................................................................. 9
          Venture Financing......................................................................................................................................................................... 11
             Nautilus Neurosciences Raises $18 Million In Venture Financing............................................................................................. 11
             Nautilus Neurosciences Secures $14.5 Million In Series A Round Of Financing ...................................................................... 13
             Nautilus Neurosciences Secures $13 Million In Venture Financing .......................................................................................... 14
          Partnerships.................................................................................................................................................................................. 15
             Nautilus Neurosciences Enters Into Co-Promotion Agreement With Mission Pharmacal Company For CAMBIA .................... 15
          Licensing Agreements .................................................................................................................................................................. 16
             Nautilus Neurosciences Enters Into Licensing Agreement With Tribute Pharma For CAMBIA ................................................. 16
       Nautilus Neurosciences, Inc. - Key Competitors .............................................................................................................................. 17
       Key Employees ............
								
To top